p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases

Alberto Righi, Marco Gambarotti, Marta Sbaraglia, Andrea Sisto, Stefano Ferrari, Angelo P. Dei Tos, Piero Picci

Research output: Contribution to journalArticle

Abstract

The potential prognostic and predictive value of p16 in high-grade localized osteosarcoma of the extremities has been recently investigated in small series of cases, and the results from different studies were somewhat controversial. A retrospective immunohistochemical analysis of p16 expression was performed in a series of 357 patients, included in different neoadjuvant chemotherapy protocols from 1986 to 2010, to explore its potential prognostic and predictive value. Immunohistochemistry was performed with a commercially available p16 monoclonal mouse antibody. Follow-up data were available in all cases with a median of 120 months. Positivity for p16 was detected in 70.6% (252/357) of cases. The p16 expression did not differ by age, sex, tumor site, histologic subtype, tumor volume, surgical margin, serum alkaline phosphatase levels, and lactate dehydrogenase levels. In the different chemotherapy protocols included, the incidence of p16 expression was similar. The absence of p16 expression was significantly associated with an adverse disease-free survival (P = .04) and overall survival (P = .05) when compared with the presence of p16 expression. At the multivariate Cox regression analysis, p16 expression lost its prognostic significance. Multivariate logistic regression analysis showed that as p16 expression was the only statistically significant parameter to predict the pathological response to neoadjuvant chemotherapy treatment with an odds ratio of 3.025 (P < .001) for “good” chemotherapy response. Our data indicate that the negative expression of p16 is associated with a reduced rate of good response to primary chemotherapy and to a worse probability of survival, although it was not confirmed as an independent prognostic biomarker after multivariate analysis.

Original languageEnglish
Pages (from-to)15-23
Number of pages9
JournalHuman Pathology
Volume58
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Osteosarcoma
Extremities
Drug Therapy
Regression Analysis
Neoadjuvant Therapy
Survival
Tumor Burden
L-Lactate Dehydrogenase
Disease-Free Survival
Alkaline Phosphatase
Multivariate Analysis
Biomarkers
Logistic Models
Immunohistochemistry
Odds Ratio
Monoclonal Antibodies
Incidence
Serum
Neoplasms

Keywords

  • Immunohistochemistry
  • Osteosarcoma
  • p16
  • Predictive factor
  • Prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities : an analysis of 357 cases. / Righi, Alberto; Gambarotti, Marco; Sbaraglia, Marta; Sisto, Andrea; Ferrari, Stefano; Dei Tos, Angelo P.; Picci, Piero.

In: Human Pathology, Vol. 58, 01.12.2016, p. 15-23.

Research output: Contribution to journalArticle

Righi, Alberto ; Gambarotti, Marco ; Sbaraglia, Marta ; Sisto, Andrea ; Ferrari, Stefano ; Dei Tos, Angelo P. ; Picci, Piero. / p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities : an analysis of 357 cases. In: Human Pathology. 2016 ; Vol. 58. pp. 15-23.
@article{b2ba7b50bfd0444d8e3fd3c5b1b193f1,
title = "p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases",
abstract = "The potential prognostic and predictive value of p16 in high-grade localized osteosarcoma of the extremities has been recently investigated in small series of cases, and the results from different studies were somewhat controversial. A retrospective immunohistochemical analysis of p16 expression was performed in a series of 357 patients, included in different neoadjuvant chemotherapy protocols from 1986 to 2010, to explore its potential prognostic and predictive value. Immunohistochemistry was performed with a commercially available p16 monoclonal mouse antibody. Follow-up data were available in all cases with a median of 120 months. Positivity for p16 was detected in 70.6{\%} (252/357) of cases. The p16 expression did not differ by age, sex, tumor site, histologic subtype, tumor volume, surgical margin, serum alkaline phosphatase levels, and lactate dehydrogenase levels. In the different chemotherapy protocols included, the incidence of p16 expression was similar. The absence of p16 expression was significantly associated with an adverse disease-free survival (P = .04) and overall survival (P = .05) when compared with the presence of p16 expression. At the multivariate Cox regression analysis, p16 expression lost its prognostic significance. Multivariate logistic regression analysis showed that as p16 expression was the only statistically significant parameter to predict the pathological response to neoadjuvant chemotherapy treatment with an odds ratio of 3.025 (P < .001) for “good” chemotherapy response. Our data indicate that the negative expression of p16 is associated with a reduced rate of good response to primary chemotherapy and to a worse probability of survival, although it was not confirmed as an independent prognostic biomarker after multivariate analysis.",
keywords = "Immunohistochemistry, Osteosarcoma, p16, Predictive factor, Prognosis",
author = "Alberto Righi and Marco Gambarotti and Marta Sbaraglia and Andrea Sisto and Stefano Ferrari and {Dei Tos}, {Angelo P.} and Piero Picci",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.humpath.2016.07.023",
language = "English",
volume = "58",
pages = "15--23",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities

T2 - an analysis of 357 cases

AU - Righi, Alberto

AU - Gambarotti, Marco

AU - Sbaraglia, Marta

AU - Sisto, Andrea

AU - Ferrari, Stefano

AU - Dei Tos, Angelo P.

AU - Picci, Piero

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The potential prognostic and predictive value of p16 in high-grade localized osteosarcoma of the extremities has been recently investigated in small series of cases, and the results from different studies were somewhat controversial. A retrospective immunohistochemical analysis of p16 expression was performed in a series of 357 patients, included in different neoadjuvant chemotherapy protocols from 1986 to 2010, to explore its potential prognostic and predictive value. Immunohistochemistry was performed with a commercially available p16 monoclonal mouse antibody. Follow-up data were available in all cases with a median of 120 months. Positivity for p16 was detected in 70.6% (252/357) of cases. The p16 expression did not differ by age, sex, tumor site, histologic subtype, tumor volume, surgical margin, serum alkaline phosphatase levels, and lactate dehydrogenase levels. In the different chemotherapy protocols included, the incidence of p16 expression was similar. The absence of p16 expression was significantly associated with an adverse disease-free survival (P = .04) and overall survival (P = .05) when compared with the presence of p16 expression. At the multivariate Cox regression analysis, p16 expression lost its prognostic significance. Multivariate logistic regression analysis showed that as p16 expression was the only statistically significant parameter to predict the pathological response to neoadjuvant chemotherapy treatment with an odds ratio of 3.025 (P < .001) for “good” chemotherapy response. Our data indicate that the negative expression of p16 is associated with a reduced rate of good response to primary chemotherapy and to a worse probability of survival, although it was not confirmed as an independent prognostic biomarker after multivariate analysis.

AB - The potential prognostic and predictive value of p16 in high-grade localized osteosarcoma of the extremities has been recently investigated in small series of cases, and the results from different studies were somewhat controversial. A retrospective immunohistochemical analysis of p16 expression was performed in a series of 357 patients, included in different neoadjuvant chemotherapy protocols from 1986 to 2010, to explore its potential prognostic and predictive value. Immunohistochemistry was performed with a commercially available p16 monoclonal mouse antibody. Follow-up data were available in all cases with a median of 120 months. Positivity for p16 was detected in 70.6% (252/357) of cases. The p16 expression did not differ by age, sex, tumor site, histologic subtype, tumor volume, surgical margin, serum alkaline phosphatase levels, and lactate dehydrogenase levels. In the different chemotherapy protocols included, the incidence of p16 expression was similar. The absence of p16 expression was significantly associated with an adverse disease-free survival (P = .04) and overall survival (P = .05) when compared with the presence of p16 expression. At the multivariate Cox regression analysis, p16 expression lost its prognostic significance. Multivariate logistic regression analysis showed that as p16 expression was the only statistically significant parameter to predict the pathological response to neoadjuvant chemotherapy treatment with an odds ratio of 3.025 (P < .001) for “good” chemotherapy response. Our data indicate that the negative expression of p16 is associated with a reduced rate of good response to primary chemotherapy and to a worse probability of survival, although it was not confirmed as an independent prognostic biomarker after multivariate analysis.

KW - Immunohistochemistry

KW - Osteosarcoma

KW - p16

KW - Predictive factor

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84987948217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987948217&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.07.023

DO - 10.1016/j.humpath.2016.07.023

M3 - Article

AN - SCOPUS:84987948217

VL - 58

SP - 15

EP - 23

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -